Two years have passed since WHO declared a pandemic state for SARS-CoV-2 infection.
COVID-19 pathogenesis consists of a first viral phase responsible for early symptoms …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic, caused by a newly
discovered coronavirus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2) …

Almost 2 years have passed since the World Health Organization declared a pandemic state
for severe acute respiratory syndrome coronavirus 2 infection. The pathogenesis of …

Background. It has been found that there is overactivation of immune response in patients
with COVID‐19. Several studies are going on to assess the role of immunomodulation. IL‐6 …

Introduction SARS-CoV-2 pneumonia is often associated with hyper-inflammation. The
cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 …

Background Interleukin-6 signal blockade showed preliminary beneficial effects in treating
inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein …

Background Elevated proinflammatory cytokines have been associated with 2019
coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an …

Background Elevated proinflammatory cytokines are associated with greater COVID-19
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …

Importance and objective The aim of this pragmatic, embedded, adaptive trial was to
measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added …

The objective of this study was to investigate the efficacy and safety of early treatment with
sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods …